A novel method to quantify and characterize leukemia-reactive natural killer cells in patients undergoing allogeneic hematopoietic stem cell transplantation following conventional or reduced-dose conditioning

International Journal of Hematology

Volumn 85, Issue 4, 2007, Pages 326-332

  Penack, Olaf ^a   Fischer, Lars ^a   Stroux, Andrea ^a   Gentilini, Chiara ^a   Nogai, Axel ^a   Muessig, Arne ^a   Ganepola, Susanne ^a   Lange, Thoralf ^b   Kliem, Constanze ^b   Marinets, Olga ^a   Blau, Igor Wolfgang ^a   Thiel, Eckhard ^a   Uharek, Lutz ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

CD107a; Natural killer cells; Stem cell transplantation

Indexed keywords

ALEMTUZUMAB; CD56 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; IBRITUMOMAB TIUXETAN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; THIOTEPA; THYMOCYTE ANTIBODY; TREOSULFAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DEGRANULATION; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; LEUKEMIA; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONMYELOABLATIVE CONDITIONING; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD56; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KILLER CELLS, NATURAL; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; MALE; MIDDLE AGED; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 34547541770     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.E0622     Document Type: Article

References (16)

1. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004;294:15-22.
2. neg cells are responsible for natural cytotoxicity against tumor targets. Leukemia. 2005;19:835-840.
3. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097-2100.
4. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature. 2001;411:385-389.
5. Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 2003;101:1620-1629.
6. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756-763.
7. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390-3400.
8. Gallagher R, Collins S, Trujillo J, et al. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood. 1979;54:713-733.
9. Lozzio BB, Lozzio CB. Properties and usefulness of the original K-562 human myelogenous leukemia cell line. Leuk Res. 1979;3: 363-370.
10. Vitale C, Chiossone L, Morreale G, et al. Analysis of the activating receptors and cytolytic function of human natural killer cells undergoing in vivo differentiation after allogeneic bone marrow transplantation. Eur J Immunol. 2004;34:455-460.
11. - natural killer cells is selectively responsible for both cell proliferation and interferon-γ production upon interaction with dendritic cells. Eur J Immunol. 2004;34:1715-1722.
12. Larosa F, Marmier C, Robinet E, et al. Peripheral T-cell expansion and low infection rate after reduced-intensity conditioning and allogeneic blood stem cell transplantation. Bone Marrow Transplant. 2005;35:859-868.
13. Mohty M, Gaugler B, Faucher C, et al. Recovery of lymphocyte and dendritic cell subsets following reduced intensity allogeneic bone marrow transplantation. Hematology. 2002;7:157-164.
14. Scholl S, Mugge LO, Issa MC, et al. Impact of early NK cell recovery on development of GvHD and CMV reactivation in dose-reduced regimen prior to allogeneic PBSCT. Bone Marrow Transplant. 2005; 35:183-190.
15. + natural killer cells after bone marrow transplantation. Blood. 1992;79:3239-3244.
16. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22:633-640.